• ADC Therapeutics’ partner Tanabe Pharma filed for Japanese approval of Zynlonta for relapsed or refractory diffuse large B-cell lymphoma.
• The application covers patients who have received at least two prior lines of systemic therapy.
• Phase 1/2 results already presented at the Japanese Society of Hematology meeting showed tumor responses consistent with global findings, without new safety concerns.
• Tanabe granted Nippon Shinyaku exclusive Japanese commercialization rights, while retaining responsibility for development and regulatory approval.
• Acceptance of the application and the first commercial sale would trigger milestones under the existing licensing agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610290730PR_NEWS_USPR_____NY84209) on October 29, 2026, and is solely responsible for the information contained therein.